Yu. Yu. Dyakonova

Yu. Yu. Dyakonova

Auto-generated profile, based on publicly available information

Yu. Yu. Dyakonova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
NMN. V. Myakova
N. V. Myakova
DLD. V. Litvinov
D. V. Litvinov
LSL. N. Shelikhova
L. N. Shelikhova
MMMichael Maschan
Michael Maschan
ЮДЮ. Ю. Дьяконова
Ю. Ю. Дьяконова
Despite remarksble improvements in the treatment of pediatric acute limphoblastic leukemia (ALL) over last decades, relapse still caries a poor prognosis with considerable morbidity and mortality. New strategies and approaches are extremely needed. According to the results of previous protocol ALL-REZ-2014 despite the implementation of bortezomib, as well as idarubicin and navelbine, which have not been used in first-line therapy, the new protocol had demonstrated no significant improvement in reaching a steady remission, especially for B-ALL relapses. The therapy results for the high risk group patients still far from optimal due to refractoriness to chemotherapy, death from infectious complications, as well as acute chemotherapy toxicity. This article demonstrates first results of pilot protocol All-REZ-2016 for high risk ALL relapses, which was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. Between 01.08.2016 and 01.12.2018 42 patients from our center were enrolled in ALL-REZ-2016 study. Patients aged 1-18 years with a first relapse of ALL without t(9;22) translocation were eligible , we included only high risk groups (S3, S4, S5) patients in this study. CD3+ apheresis was made before treatment for all patients with B-cell phenotype. To determine the efficiency and toxicity of fludarabine- and clofarabine-including chemotherapy regimens after the preliminary phase with prednisone 60mg/m2, for patients with B-ALL randomization for blocks with fludarabine or clofarabine was performed. The next stage of the therapy was a course with blinatumomab (28 days) and weekly autologous lymphocyte infusions (x 4). ALL patients with T-ALL got 11 days of protocol N, and then studying the efficiency of clofarabine 52 mg/m2 for TIII/TIV was planned, since nelarabine has been shown to be inefficient for this category. For the patients with TI/II ALL, nelarabine 650 mg/m2 therapy was given after protocol N. If remission was attained, a stem cell transplant was performed for all patients without delay. 42 patients were enrolled, the median age was 9.9 years (range 2.7-16.2), there was male predominance (63.8%), the majority had B-cell phenotype (61.7%). The estimated 2-year event-free survival (EFS) across all immunophenotypes was 47.7% (SE+/-8%) and a cumulative incidence of second relapse (CIR) was 27.1% (SE+/-7.6%). Patients with B-ALL had EFS 55% +/-10% and CIR 30.0% +/-9.9%, T-ALL had EFS 35% +/-13% and CIR 21.2+/-12%. We did not observe serious toxicity when using blinatumomab. The use of clofarabine and fludarabine was accompanied by deep immunosuppression and severe infectious episodes. Results for patients with B-cell relapses are much better then in previous protocol ALL-REZ-2014, using of autologous CD3+ lymphocytes infusion once a week during the continuous blinatumomab therapy is effective. For T-ALL relapses results remain unsatisfactory due to refractoriness, but number of patients is still small for final conclusions.

10 August 2017 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Closed access
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
OBO. I. Bydanov
O. I. Bydanov
NMN. V. Myakova
N. V. Myakova
YAYu. G. Abugova
Yu. G. Abugova
OAO. V. Aleynikova
O. V. Aleynikova
AKA. I. Karachunsky
A. I. Karachunsky
The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This is due both to the difficulties of achieving a second remission and to the problems of organizing allogeneic bone marrow transplantation (BMT) in those patients who need it. The standard approach is the use of second-line drugs in the regime of high-dosage chemotherapy blocks, but the response rate for this treatment in patients with early relapses remains low and the response time is short. Recently, new drugs with different mechanisms of action have appeared that can give an opportunity for a full remission. The organization of a multicentre study on anti-relapse therapy in the Russian Federation is an urgent task, the solution of which can help in studying new approaches to therapy and in the organization of BMT logistics. This article presents the results of a pilot multicentre study on the treatment of relapses of ALL in children in the Russian Federation. The effectiveness of standard therapy for a group with late relapses and the efficacy and toxicity of interventional blocks with the use of bortezomib, clofarabine, nelarabine are presented.

20 April 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DED. A. Evstratov
D. A. Evstratov
NMN. V. Myakova
N. V. Myakova
APA. V. Pshonkin
A. V. Pshonkin
YAYu. G. Abugova
Yu. G. Abugova
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
ЮДЮ. Ю. Дьяконова
Ю. Ю. Дьяконова
The reduction of long-term survival and fertility is still a problem in management of Hodgkin lymphoma in children and adolescents. These problems are partly solved by reduction of radiotherapy and changing procarbazine on etoposide and dacarbazine. We analyzed medical data of patients with HL 18 years that were treated by modified OEPA-COPDAC protocol since 1.01.2012 to 01.12.2017. The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. All patients despite gender didn't receive procarbazine. We analyzed data of 77 patients. Event-free survival (EFS) was 88% (95% CI 76.2-93.9%). EFS didn't differ between boys and girls 86.9% (95% CI 67.8-94.7%) and 88.7% (95% CI 67.3-96.1%) respectively (р = 0,9). EFS was significantly higher in patients without E-lesions compared with patients with E-lesions 90.8% (95% CI 77.8-96.2) and 72.7% (95% CI 28.4-89.6) respectively (p = 0.04). We analyzed toxicity of 40 cycles OEPA and 44 cycles COPDAC. Toxicity was acceptable. In our study we didn't detect significant difference in EFS in boys and girls. Procarbazine can be safely changed on etoposide in OPPA and dacarbazine in COPP in boys and girls with HL. E-lesions is a risk factor of inferior EFS.

14 February 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
DED. A. Evstratov
D. A. Evstratov
ASA. D. Shutova
A. D. Shutova
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
SRS. A. Radygina
S. A. Radygina
YAYu. G. Abugova
Yu. G. Abugova
ЮДЮ. Ю. Дьяконова
Ю. Ю. Дьяконова
Today, treatment results for acute lymphoblastic leukemia (ALL) look encouraging, yet 10–15% patients still end up relapsing. The success of relapse treatment is directly dependent on whether or not a tumor clone has been completely eradicated before hematopoietic stem cell transplantation (HSCT). Immunotherapy made it possible to achieve minimal residual disease (MRD) – negative remission even in refractory patients. One example of such immunotherapeutic agents is inotuzumab ozogamicin (InO), an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent calicheamicin. We included 17 patients under the age of 18 with relapsed or refractory precursor B-cell ALL (pre-B ALL) who had been treated with InO at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of Russia from 01.10.2016 to 01.09.2022. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The efficacy of the therapy was assessed based on the patients’ morphological response, MRD negativity and overall survival. Treatment toxicity was assessed according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events). Statistical analysis was performed using the XLSTAT 2016 software. The majority of the patients (75%) responded to the therapy. MRD negativity was achieved in 41.2% of the study patients. The one-year overall survival rate was 40.3% (95% confidence interval 14.8–65.7). The treatment was well tolerated but 33% of the patients treated with standard-dose InO and subsequent HSCT developed veno-occlusive disease/sinusoidal obstruction syndrome. In our study, we demonstrated the high efficacy of InO both when used as a rescue therapy in patients with relapsed/refractory pre-B ALL and as a bridging therapy in patients before HSCT.

21 April 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GSGarik Sagoyan
Garik Sagoyan
LAL. Kh. Anderzhanova
L. Kh. Anderzhanova
YDYu. Yu. Dyakonova
Yu. Yu. Dyakonova
DAD. S. Abramov
D. S. Abramov
ASA. P. Shcherbakov
A. P. Shcherbakov
ЮДЮ. Ю. Дьяконова
Ю. Ю. Дьяконова
B-cell lymphoma is unclassifiable, with signs intermediate between diffuse large-cell B-cell lymphoma and Hodgkin's lymphoma (LH), is a rare aggressive lymphoma with an uncertain prognosis that has specific morphological and immunophenotypic characteristics characteristic of both diffuse B-large-cell lymphoma and Hodgkin's lymphoma. In this article, the comparative characteristics of NIVCL and various variants of large cell B-cell lymphomas are presented, as well as a description of the clinical case of NVCL in a child of 3 years. Patient's parents agreed to use personal dats and photos in research and publications.

13 August 2018 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
DED.A. Evstratov
D.A. Evstratov
PZP.A. Zharkov
P.A. Zharkov
APA.V. Pshonkin
A.V. Pshonkin
YAY.G. Abugova
Y.G. Abugova
NMN.V. Myakova
N.V. Myakova
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.